18th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies
Leonard G. Gomella, MD, FACS; Maha Hussain, MD, FACP, FASCO; Daniel P. Petrylak, MD
Release Date: April 8, 2025
Expiration Date: May 13, 2025
Activity Overview
This educational activity is an archive of the live presentation held on March 28-29, 2025.
For more information about this educational activity, faculty, and disclosures, please click here.
Target Audience
This educational activity is directed toward medical, surgical, and radiation oncologists involved in the treatment of patients with GU malignancies. Urologists, fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, nuclear medicine physicians, and other health care professionals interested in the treatment of GU malignancies may also participate.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Identify key diagnostic, prognostic, and therapeutic biomarkers that inform evidence-based treatment strategies for GU cancers.
- Evaluate emerging safety and efficacy data from recently reported clinical trials on novel therapeutic strategies in GU malignancies.
- Assess the impact of recent landmark clinical trial data on the standards of care for the treatment of GU malignancies.
- Determine effective strategies to monitor and mitigate adverse events associated with systemic therapies in GU cancer care.
Leonard G. Gomella, MD, FACS
The Bernard W. Godwin Professor of Prostate Cancer
Chairman, Department of Urology
Senior Director for Clinical Affairs Director
Thomas Jefferson University
Sidney Kimmel Comprehensive Cancer Center
Philadelphia, PA
Maha Hussain, MD, FACP, FASCO
Genevieve E. Teuton Professor of Medicine
Professor, Medicine (Hematology/Oncology)
Deputy Director
Robert H. Lurie Comprehensive Cancer Center
Northwestern University Feinberg School of Medicine
Chicago, IL
Daniel P. Petrylak, MD
Professor of Medicine (Medical Oncology) and Urology
Director, Prostate and Genitourinary Medical Oncology
Director, Prostate Cancer Translational Research Group
Yale School of Medicine
Yale Cancer Center
New Haven, CT
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.